205 related articles for article (PubMed ID: 15096536)
21. Characterization of C1 inhibitor binding to neutrophils.
Chang NS; Boackle RJ; Leu RW
Immunology; 1991 May; 73(1):95-101. PubMed ID: 2045131
[TBL] [Abstract][Full Text] [Related]
22. Studies of the inhibition of C56-initiated lysis (reactive lysis). IV. Antagonism of the inhibitory activity c567-INH by poly-L-lysine.
McLeod B; Baker P; Behrends C; Gewurz H
Immunology; 1975 Feb; 28(2):379-90. PubMed ID: 47309
[TBL] [Abstract][Full Text] [Related]
23. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury.
Buerke M; Prüfer D; Dahm M; Oelert H; Meyer J; Darius H
J Pharmacol Exp Ther; 1998 Jul; 286(1):429-38. PubMed ID: 9655888
[TBL] [Abstract][Full Text] [Related]
24. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1).
Windfuhr JP; Alsenz J; Loos M
Mol Immunol; 2005 Apr; 42(6):657-63. PubMed ID: 15781109
[TBL] [Abstract][Full Text] [Related]
25. Cross-species function of the pig C1 esterase inhibitor.
Koboyashi C; Matsunami K; Omori T; Nakahata K; Nakatsu S; Xu H; Gao C; Ihara Y; Fukuzawa M; Miyagawa S
Transplant Proc; 2006 Dec; 38(10):3321-2. PubMed ID: 17175261
[TBL] [Abstract][Full Text] [Related]
26. A surface-bound form of human C1 esterase inhibitor improves xenograft rejection.
Matsunami K; Miyagawa S; Yamada M; Yoshitatsu M; Shirakura R
Transplantation; 2000 Mar; 69(5):749-55. PubMed ID: 10755521
[TBL] [Abstract][Full Text] [Related]
27. In vitro Inhibition of Canine Complement-Mediated Hemolysis.
Hernandez DM; Goggs R; Behling-Kelly E
J Vet Intern Med; 2018 Jan; 32(1):142-146. PubMed ID: 29171101
[TBL] [Abstract][Full Text] [Related]
28. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
29. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.
Caliezi C; Wuillemin WA; Zeerleder S; Redondo M; Eisele B; Hack CE
Pharmacol Rev; 2000 Mar; 52(1):91-112. PubMed ID: 10699156
[TBL] [Abstract][Full Text] [Related]
30. TagA is a secreted protease of Vibrio cholerae that specifically cleaves mucin glycoproteins.
Szabady RL; Yanta JH; Halladin DK; Schofield MJ; Welch RA
Microbiology (Reading); 2011 Feb; 157(Pt 2):516-525. PubMed ID: 20966091
[TBL] [Abstract][Full Text] [Related]
31. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.
Bos IG; van Mierlo GJ; Bleeker WK; Rigter GM; te Velthuis H; Dickneite G; Hack CE
Int Immunopharmacol; 2001 Aug; 1(8):1583-95. PubMed ID: 11515821
[TBL] [Abstract][Full Text] [Related]
32. A solid-phase antibody capture assay for the measurement of C1-inhibitor consumption in vivo.
Wallace EM; Feighery C; Jackson J
Scand J Clin Lab Invest; 1996 Feb; 56(1):1-9. PubMed ID: 8850166
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity.
Thorgersen EB; Ludviksen JK; Lambris JD; Sfyroera G; Nielsen EW; Mollnes TE
Innate Immun; 2010 Aug; 16(4):254-64. PubMed ID: 19710096
[TBL] [Abstract][Full Text] [Related]
34. Proteolytic inactivation of plasma C1- inhibitor in sepsis.
Nuijens JH; Eerenberg-Belmer AJ; Huijbregts CC; Schreuder WO; Felt-Bersma RJ; Abbink JJ; Thijs LG; Hack CE
J Clin Invest; 1989 Aug; 84(2):443-50. PubMed ID: 2668333
[TBL] [Abstract][Full Text] [Related]
35. How
Abreu AG; Barbosa AS
Front Immunol; 2017; 8():452. PubMed ID: 28473832
[TBL] [Abstract][Full Text] [Related]
36. C1-esterase inhibitor in ischemia and reperfusion.
Horstick G
Immunobiology; 2002 Sep; 205(4-5):552-62. PubMed ID: 12396015
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
[TBL] [Abstract][Full Text] [Related]
38. Regulation of C1-inhibitor synthesis by interferons and other agents.
Lappin D; Whaley K
Behring Inst Mitt; 1989 Jul; (84):180-92. PubMed ID: 2478116
[TBL] [Abstract][Full Text] [Related]
39. Complement C1-inhibitor expression in Alzheimer's disease.
Veerhuis R; Janssen I; Hoozemans JJ; De Groot CJ; Hack CE; Eikelenboom P
Acta Neuropathol; 1998 Sep; 96(3):287-96. PubMed ID: 9754962
[TBL] [Abstract][Full Text] [Related]
40. C1-inhibitor efficiently delays clot development in normal human whole blood and inhibits Escherichia coli-induced coagulation measured by thromboelastometry.
Landsem A; Fure H; Mollnes TE; Nielsen EW; Brekke OL
Thromb Res; 2016 Jul; 143():63-70. PubMed ID: 27197075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
